Notably, mutations in SETD2, an RNA polymerase II–associated histone methyltransferase known to promote metastasis in multiple cancers including renal cell carcinoma [21], were markedly more frequent in the high-risk group (14%) compared with the low-risk group (< 4%). The gene discussed is PRDM9; the disease is renal cell carcinoma.